Systemic Lupus Erythematosus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report View Sample

Published: September 30, 2022 Report Code: GDGMDHC22332IDB-ST

Select Item

Systemic Lupus Erythematosus Pipeline Drugs Market Report Overview

The inflammation triggered by Systemic Lupus Erythematosus (SLE) affects many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender, and hormones.

The Systemic Lupus Erythematosus pipeline market research report provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects.

Key Targets Tyrosine Protein Kinase BTK, Interleukin 2 Receptor, Toll Like Receptor 7, Tumor Necrosis Factor Ligand Superfamily Member 13B, Tyrosine Protein Kinase JAK1, CD40 Ligand, Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing B Lymphocyte Antigen CD20, Non Receptor Tyrosine Protein Kinase TYK2, Toll Like Receptor, and Others
Key Mechanisms of Action Tyrosine Protein Kinase BTK Inhibitor, Interleukin 2 Receptor Agonist, Toll Like Receptor 7 Antagonist, Tumor Necrosis Factor Ligand Superfamily Member 13B Inhibitor, Tyrosine Protein Kinase JAK1 Inhibitor, CD40 Ligand Inhibitor, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Non Receptor Tyrosine Protein Kinase TYK2 Inhibitor, Toll Like Receptor 8 Antagonist, and Others
Key Routes of Administration Oral, Intravenous, Subcutaneous, Parenteral, Intravenous Drip, Intramuscular, Intrathecal, Ophthalmic, Topical, Inhalational, and Others
Key Molecule Type Small Molecule, Monoclonal Antibody, Fusion Protein, Cell Therapy, Gene-Modified Cell Therapy, Recombinant Protein, Biologic, Synthetic Peptide, Protein, Antibody, and Others
Leading Players Novartis AG, Bristol-Myers Squibb Co, Johnson & Johnson, AbbVie Inc, Biogen Inc, Resolve Therapeutics LLC, Alexion Pharmaceuticals Inc, Alpine Immune Sciences Inc, Aurinia Pharmaceuticals Inc, and F. Hoffmann-La Roche Ltd

Systemic Lupus Erythematosus Pipeline Products Market Segmentation by Targets

The key targets in the Systemic Lupus Erythematosus pipeline products market are Tyrosine Protein Kinase BTK, Interleukin 2 Receptor, Toll Like Receptor 7, Tumor Necrosis Factor Ligand Superfamily Member 13B, Tyrosine Protein Kinase JAK1, CD40 Ligand, Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing B Lymphocyte Antigen CD20, Non Receptor Tyrosine Protein Kinase TYK2, Toll Like Receptor 8, and others. Tyrosine Protein Kinase BTK was the largest target in 2022.

Systemic Lupus Erythematosus Pipeline Products Market Analysis by Targets, 2022 (%)

Systemic Lupus Erythematosus Pipeline Products Market Analysis by Targets

For more target insights into the Systemic Lupus Erythematosus pipeline products market, download a free report sample

Systemic Lupus Erythematosus Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the Systemic Lupus Erythematosus pipeline products market are Tyrosine Protein Kinase BTK Inhibitor, Interleukin 2 Receptor Agonist, Toll Like Receptor 7 Antagonist, Tumor Necrosis Factor Ligand Superfamily Member 13B Inhibitor, Tyrosine Protein Kinase JAK1 Inhibitor, CD40 Ligand Inhibitor, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Non Receptor Tyrosine Protein Kinase TYK2 Inhibitor, Toll Like Receptor 8 Antagonist, and others. Tyrosine Protein Kinase BTK Inhibitor was the largest MoA in the pipeline market in 2022.

Systemic Lupus Erythematosus Pipeline Products Market Analysis by Mechanisms of Action, 2022 (%)

Systemic Lupus Erythematosus Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights into the Systemic Lupus Erythematosus pipeline products market, download a free report sample

Systemic Lupus Erythematosus Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the Systemic Lupus Erythematosus pipeline products market are oral, intravenous, subcutaneous, parenteral, intravenous drip, intramuscular, intrathecal, ophthalmic, topical, inhalational, and others. The majority of the pipeline products were administered orally in 2022.

Systemic Lupus Erythematosus Pipeline Products Market Analysis by Routes of Administration, 2022 (%)

Systemic Lupus Erythematosus Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights into the Systemic Lupus Erythematosus pipeline products market, download a free report sample

Systemic Lupus Erythematosus Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the Systemic Lupus Erythematosus pipeline products market are small molecule, monoclonal antibody, fusion protein, cell therapy, gene-modified cell therapy, recombinant protein, biologic, synthetic peptide, protein, antibody, and others.

Systemic Lupus Erythematosus Pipeline Products Market Analysis by Molecule Types, 2022 (%)

Systemic Lupus Erythematosus Pipeline Products Market Analysis by Molecule Types

For more molecule type insights into the Systemic Lupus Erythematosus pipeline products market, download a free report sample

Systemic Lupus Erythematosus Pipeline Products Market - Competitive Landscape

Some of the leading players in the Systemic Lupus Erythematosus pipeline products market are Novartis AG, Bristol-Myers Squibb Co, Johnson & Johnson, AbbVie Inc, Biogen Inc, Resolve Therapeutics LLC, Alexion Pharmaceuticals Inc, Alpine Immune Sciences Inc, Aurinia Pharmaceuticals Inc, and F. Hoffmann-La Roche Ltd.

Systemic Lupus Erythematosus Pipeline Products Market Analysis by Players, 2022 (%)

Systemic Lupus Erythematosus Pipeline Products Market Analysis by Players

To know more about the leading players in the Systemic Lupus Erythematosus pipeline products market, download a free report sample

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus (Immunology).

  • The pipeline guide reviews pipeline therapeutics for Systemic Lupus Erythematosus (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Systemic Lupus Erythematosus (Immunology) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Systemic Lupus Erythematosus (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews the latest news related to pipeline therapeutics for Systemic Lupus Erythematosus (Immunology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Systemic Lupus Erythematosus (Immunology).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus (Immunology) pipeline depth and focus on Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

AbbVie Inc
Abcentra LLC
Accro Bioscience Suzhou Co Ltd
Alexion Pharmaceuticals Inc
Alphamab Oncology
Alpine Immune Sciences Inc
Aluda Pharmaceuticals Inc
Amgen Inc
Ampio Pharmaceuticals Inc
Annexon Inc
Apellis Pharmaceuticals Inc
Apimeds Inc
APT Therapeutics Inc
Aqualung Therapeutics Corp
Argenx SE
Aria Pharmaceuticals Inc
Asahi Kasei Pharma Corp
AskGene Pharma Inc
Astellas Pharma Inc
AstraZeneca Plc
Athos Therapeutics Inc
Aurinia Pharmaceuticals Inc
Avotres Inc
BeiGene Ltd
Beijing Mabworks Biotech Co Ltd
Beijing Toll Biotech Co Ltd
Bio-Path Holdings Inc
BioAegis Therapeutics Inc
Biocon Ltd
Biogen Inc
BioTherapeutics Inc
Boehringer Ingelheim International GmbH
Boston Pharmaceuticals Inc
Bristol-Myers Squibb Co
Capricor Therapeutics Inc
Captor Therapeutics SA
Carna Biosciences Inc
Cellenkos Inc
CellionBioMed Inc
Cells for Cells SA
Centessa Pharmaceuticals Plc
Centivax Inc
ChemoCentryx Inc
Chinook Therapeutics Inc
Chong Kun Dang Pharmaceutical Corporation
Chugai Pharmaceutical Co Ltd
Citryll BV
Corbus Pharmaceuticals Inc
Corestem Inc
Coya Therapeutics Inc
CSL Ltd
CSPC Pharmaceutical Group Ltd
Cugene Inc
CuraVac Inc
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Domainex Ltd
Eisai Co Ltd
Eledon Pharmaceuticals Inc
Eli Lilly and Co
Ermium Therapeutics SAS
Evopoint Bioscience Co Ltd
Exinda Therapeutics LLC
F. Hoffmann-La Roche Ltd
Foshan Rexie Biotechnology Co Ltd
Fresh Tracks Therapeutics Inc
Galapagos NV
Genentech USA Inc
General Nanotherapeutics LLC
Generos Biomedical Technology (Hangzhou) Co Ltd
GeneScience Pharmaceuticals Co Ltd
Genesen Co Ltd
Genovax Srl
Genrix (Shanghai) Biopharmaceutical Co Ltd
Good T Cells Inc
GSK plc
Guangzhou BeBetter Medicine Technology Co Ltd
H. Lundbeck AS
HanAll Biopharma Co Ltd
Hanmi Pharmaceuticals Co Ltd
HemoGenyx Pharmaceuticals Plc
Horizon Therapeutics Plc
Huabo Biopharm (Shanghai) Co Ltd
iCELL Biotechnology Co Ltd
iCell Gene Therapeutics LLC
Ichnos Sciences Inc
Idorsia Pharmaceutical Ltd
IL-2Rx Inc
Iltoo Pharma
Immplacate Inc
Immune Modulation Inc
Immungenetics AG
ImmunoBiome Inc
ImmunoQure AG
Immunwork Inc
Immupharma Plc
Inflection Biosciences Ltd
InnoCare Pharma Ltd
Innovimmune Biotherapeutics Inc
iSD Immunotech ApS
JAMM Therapeutics Ltd
Janus Biotherapeutics Inc
Jiangsu Hengrui Medicine Co Ltd
JiangSu Qyuns Therapeutics Co Ltd
Johnson & Johnson
Jubilant Therapeutics Inc
Jura Bio Inc
Juventas Cell Therapy Ltd
Kangpu Biopharmaceuticals Ltd
Karyopharm Therapeutics Inc
KeyMed Biosciences Inc
Kezar Life Sciences Inc
Kiniksa Pharmaceuticals Ltd
Kyowa Kirin Co Ltd
Landos Biopharma Inc
Lead Discovery Center GmbH
Lepton Pharmaceuticals Ltd
MedAnnex Ltd
MENTRIK Biotech LLC
Merck & Co Inc
Merck KGaA
Microba Life Sciences Ltd
MorphoSys AG
Nanchang Hongyi Pharmaceutical Co Ltd
Nanjing Aimeifei Biomedical Technology Co Ltd
Nektar Therapeutics
Neovacs SA
Neutrolis Inc
Novartis AG
Nudge Therapeutics Inc
Octagon Therapeutics Inc
Octapharma AG
OMass Therapeutics Limited
Omeros Corp
Orbsen Therapeutics Ltd
PB Immune Therapeutics Co Ltd
Pfizer Inc
Pharchoice Therapeutics Inc
Priovant Therapeutics Inc
ProNoxis AB
Provention Bio Inc
Ra Pharmaceuticals Inc
Regen BioPharma Inc
Reistone Biopharma Co Ltd
RemeGen Co Ltd
Resolve Therapeutics LLC
Rheos Medicines Inc
Sanofi
Sareum Holdings Plc
Sarkana Pharma Inc
SBI Biotech Co Ltd
SciRhom GmbH
Sengenics Corp Pte Ltd
Serenity Bioworks Inc
Shanghai GeneChem Co Ltd
Shanghai Jiyu Pharmaceutical Technology Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai YaKe Biotechnology Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Simcere Pharmaceutical Group Ltd
SinoMab Bioscience Ltd
Slate Bio Inc
Sorrento Therapeutics Inc
Steel Therapeutics Inc
StingInn LLC
Swedish Orphan Biovitrum AB
SynAct Pharma AB
Takeda Pharmaceutical Co Ltd
Tasly Biopharmaceuticals Co Ltd
Technoderma Medicines Inc
TherapyX Inc
TolerogenixX GmbH
Tonix Pharmaceuticals Holding Corp
Transcenta Holding Ltd
Twinpigbiolab Co Ltd
UCB SA
Usynova Pharmaceuticals Ltd
Vera Therapeutics Inc
Viracta Therapeutics Inc
Visterra Inc
Vitro Biopharma Inc
XTL Biopharmaceuticals Ltd
Zenas BioPharma (USA) LLC
ZyVersa Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Systemic Lupus Erythematosus – Overview

Systemic Lupus Erythematosus – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Systemic Lupus Erythematosus – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Systemic Lupus Erythematosus – Companies Involved in Therapeutics Development

Systemic Lupus Erythematosus – Drug Profiles

Systemic Lupus Erythematosus – Dormant Projects

Systemic Lupus Erythematosus – Discontinued Products

Systemic Lupus Erythematosus – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Systemic Lupus Erythematosus, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Systemic Lupus Erythematosus – Dormant Projects, 2022

Systemic Lupus Erythematosus – Discontinued Products, 2022

Systemic Lupus Erythematosus – Discontinued Products, 2022 (Contd..1)

Figures

List of Figures

Number of Products under Development for Systemic Lupus Erythematosus, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Systemic Lupus Erythematosus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Systemic Lupus Erythematosus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Immunology reports
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Generic Drugs - Physician Perspective - Thematic Intelligence
$1,495 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Systemic Lupus Erythematosus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Systemic Lupus Erythematosus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more